LTC3412676DI2 - CYCLIC BORONIC ACID DERIVATIVES, THEIR PRODUCTION METHOD AND THERAPEUTIC USE - Google Patents

CYCLIC BORONIC ACID DERIVATIVES, THEIR PRODUCTION METHOD AND THERAPEUTIC USE

Info

Publication number
LTC3412676DI2
LTC3412676DI2 LTPA2020521C LTPA2020521C LTC3412676DI2 LT C3412676D I2 LTC3412676D I2 LT C3412676DI2 LT PA2020521 C LTPA2020521 C LT PA2020521C LT PA2020521 C LTPA2020521 C LT PA2020521C LT C3412676D I2 LTC3412676D I2 LT C3412676DI2
Authority
LT
Lithuania
Prior art keywords
production method
acid derivatives
boronic acid
therapeutic use
cyclic boronic
Prior art date
Application number
LTPA2020521C
Other languages
Lithuanian (lt)
Original Assignee
Melinta Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45565270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC3412676D(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics, Inc. filed Critical Melinta Therapeutics, Inc.
Publication of LTPA2020521I1 publication Critical patent/LTPA2020521I1/en
Publication of LTC3412676DI2 publication Critical patent/LTC3412676DI2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
LTPA2020521C 2010-08-10 2020-07-10 CYCLIC BORONIC ACID DERIVATIVES, THEIR PRODUCTION METHOD AND THERAPEUTIC USE LTC3412676DI2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37229610P 2010-08-10 2010-08-10
US201161488655P 2011-05-20 2011-05-20
PCT/US2011/046957 WO2012021455A1 (en) 2010-08-10 2011-08-08 Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP11816882.2A EP2603514B1 (en) 2010-08-10 2011-08-08 Cyclic boronic acid ester derivatives and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
LTPA2020521I1 LTPA2020521I1 (en) 2020-08-10
LTC3412676DI2 true LTC3412676DI2 (en) 2022-05-10

Family

ID=45565270

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP18183968.9T LT3412676T (en) 2010-08-10 2011-08-08 Cyclic boronic acid ester derivatives, method for the preparation and therapeutic uses thereof
LTPA2020519C LTC3412676I2 (en) 2010-08-10 2020-07-10 CYCLIC BORONIC ACID DERIVATIVES, THEIR MANUFACTURING METHOD AND THERAPEUTIC USE
LTPA2020521C LTC3412676DI2 (en) 2010-08-10 2020-07-10 CYCLIC BORONIC ACID DERIVATIVES, THEIR PRODUCTION METHOD AND THERAPEUTIC USE

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP18183968.9T LT3412676T (en) 2010-08-10 2011-08-08 Cyclic boronic acid ester derivatives, method for the preparation and therapeutic uses thereof
LTPA2020519C LTC3412676I2 (en) 2010-08-10 2020-07-10 CYCLIC BORONIC ACID DERIVATIVES, THEIR MANUFACTURING METHOD AND THERAPEUTIC USE

Country Status (27)

Country Link
US (10) US8680136B2 (en)
EP (3) EP2603514B1 (en)
JP (4) JP6266978B2 (en)
KR (3) KR101987091B1 (en)
CN (1) CN103180328B (en)
AU (1) AU2011289615B2 (en)
BR (1) BR112013003045B1 (en)
CA (1) CA2807546C (en)
CL (1) CL2013000399A1 (en)
CO (1) CO6680667A2 (en)
CY (3) CY1123208T1 (en)
DK (2) DK2603514T3 (en)
ES (2) ES2691468T3 (en)
HR (1) HRP20200741T1 (en)
HU (4) HUE040086T2 (en)
IL (1) IL224564A (en)
LT (3) LT3412676T (en)
MX (1) MX348653B (en)
MY (1) MY188960A (en)
NO (2) NO2019014I1 (en)
NZ (1) NZ607354A (en)
PL (2) PL3412676T3 (en)
PT (2) PT2603514T (en)
RS (1) RS60310B1 (en)
RU (1) RU2599791C2 (en)
SG (1) SG187757A1 (en)
WO (1) WO2012021455A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2691468T3 (en) 2010-08-10 2018-11-27 Rempex Pharmaceuticals, Inc. Derivatives of cyclic boronic acid ester and therapeutic uses thereof
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
EP2814483A2 (en) * 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014052836A2 (en) 2012-09-27 2014-04-03 Dunman Paul M Methods and compositions for treating infection
RU2654692C2 (en) * 2012-12-07 2018-05-22 Венаторкс Фармасьютикалс, Инк. Beta-lactamase inhibitors
MX2015007433A (en) 2012-12-20 2015-12-07 Inception 2 Inc Triazolone compounds and uses thereof.
JP6324409B2 (en) * 2013-01-04 2018-05-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド Boronic acid derivatives and their therapeutic use
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2016509594A (en) 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド Boronic acid derivatives and their therapeutic use
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014110442A1 (en) 2013-01-10 2014-07-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2991648A4 (en) * 2013-05-03 2017-01-18 Microbiotix, Inc. Antimicrobial potentiators
WO2015035059A1 (en) 2013-09-06 2015-03-12 Inception 2, Inc. Triazolone compounds and uses thereof
DK3140310T3 (en) 2014-05-05 2019-10-21 Rempex Pharmaceuticals Inc SYNTHESIS OF BORONATE SALTS AND USE THEREOF
EP3139930A4 (en) * 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3145936B1 (en) 2014-05-19 2020-09-30 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
RU2686740C2 (en) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3164406A4 (en) * 2014-07-01 2018-04-04 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) * 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN104447610A (en) * 2014-11-21 2015-03-25 山东金城医药化工股份有限公司 Preparation method for high-purity ethyl 2-(2-aminothiazole-4-yl)-2-(1-tert-butoxycarbonyl-1-methylethoxyimino)acetate
CN107207537B (en) * 2014-12-19 2019-05-31 莱姆派克斯制药公司 For producing the equipment and continuous flow method of boronic acid derivatives
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016172208A1 (en) 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
CN108472284A (en) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 Beta-lactamase inhibitor
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
ES2894251T3 (en) 2016-06-30 2022-02-14 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
ES2970715T3 (en) * 2016-12-22 2024-05-30 Prec Pharmaceuticals Inc Compositions and methods for inhibiting arginase activity
DK3565551T3 (en) 2017-01-09 2024-06-17 Melinta Therapeutics Inc METHODS OF TREATING BACTERIAL INFECTIONS WITH A COMBINATION OF VABORBACTAM AND MEROPENM
JOP20190188A1 (en) 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc Apparatus and continuous flow process for production of boronic acid derivative
EP3592362A4 (en) 2017-03-06 2020-09-02 Venatorx Pharmaceuticals, Inc. Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
CN110959008A (en) 2017-05-26 2020-04-03 维纳拓尔斯制药公司 Penicillin binding protein inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
JP7377545B2 (en) 2017-10-11 2023-11-10 キューペックス バイオファーマ， インコーポレイテッド Boronic acid derivatives and their synthesis
SG11202003762VA (en) * 2017-11-01 2020-05-28 Melinta Therapeutics Inc Synthesis of boronate ester derivatives and uses thereof
CN112424209A (en) 2018-04-20 2021-02-26 Qpex生物制药有限公司 Boronic acid derivatives and their therapeutic use
CN111039965B (en) * 2018-10-12 2020-12-01 新发药业有限公司 Simple preparation method of farborobactam
US20240173374A1 (en) * 2021-02-25 2024-05-30 Ohio State Innovation Foundation Liposomal formulations of boronic acid containing active agents
CN113214302B (en) * 2021-04-23 2022-06-24 四川大学 3-substituted five-membered cyclic borate derivative for inhibiting metal beta-lactamase and/or serine beta-lactamase

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4353807A (en) 1981-03-24 1982-10-12 Mobil Oil Corporation Lubricants and fuels containing boroxarophenanthrene compounds
FR2573070B1 (en) 1984-11-13 1987-01-30 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF CARBONYL COMPOUNDS
FR2574070B1 (en) 1984-11-30 1987-02-27 Stam CATALYST FOR TAKING LAUNCHED ANHYDRITE MORTARS WITH IMPROVED RESISTANCE TO HIGH TEMPERATURE AND HUMIDITY STORAGE, AND USE OF SUCH A CATALYST
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US4822786A (en) 1986-07-01 1989-04-18 Kaken Pharmaceutical Co., Ltd. Cephalosporin compounds, and antibacterial agents
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
AU8140898A (en) 1997-06-13 1998-12-30 Northwestern University Inhibitors of beta-lactamases and uses therefor
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
WO2000035905A1 (en) 1998-12-16 2000-06-22 Northwestern University INHIBITORS OF β-LACTAMASES AND USES THEREFOR
AU3124300A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
KR20020030126A (en) 1999-09-25 2002-04-22 피터 기딩스 Piperazine Derivatives as 5-HT1B Antagonists
WO2001030149A1 (en) 1999-10-28 2001-05-03 Merck & Co., Inc. Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
AU2001292732A1 (en) 2000-09-12 2002-03-26 Larry C. Blasczcak Beta-lactam analogs and uses therefor
CN1189469C (en) 2000-09-14 2005-02-16 潘斯瑞克有限公司 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acid derivatives as anti-bacterial agents
WO2002054931A2 (en) 2001-01-10 2002-07-18 Bristol Myers Squibb Company P Alpha-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (en) 2001-04-17 2002-11-07 Jerini Ag Immobilization method and arrangement of connections produced therewith on a planar surface
WO2003057144A2 (en) 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
FR2835186B1 (en) 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
JP2003229277A (en) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd Material for light emitting element, light emitting element and light emitting device using the same
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
JP3714948B2 (en) 2002-09-11 2005-11-09 呉羽化学工業株式会社 Amine compounds and uses thereof
EP2325226A1 (en) 2002-10-30 2011-05-25 Sumitomo Chemical Company, Limited Complex aryl copolymer compounds and polymer light emitting devices made by using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
WO2004058679A2 (en) 2002-12-20 2004-07-15 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (en) 2003-03-25 2009-03-04 三井化学株式会社 Azadiol complex compound and optical recording medium using the compound
US7842941B2 (en) 2003-10-06 2010-11-30 Sumitomo Chemical Company, Limited Aromatic compound
JP2007508290A (en) 2003-10-10 2007-04-05 ファイザー・プロダクツ・インク Substituted 2H- [1,2,4] triazolo [4,3-a] pyrazine as a GSK-3 inhibitor
KR100918322B1 (en) 2003-11-12 2009-09-22 페노믹스 코포레이션 Heterocyclic boronic acid compounds
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
NZ598441A (en) * 2005-02-16 2013-07-26 Anacor Pharmaceuticals Inc Boron-containing small molecules
WO2006091771A2 (en) 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
WO2006101779A2 (en) 2005-03-15 2006-09-28 The University Of Chicago Non-aqueous electrolytes for lithium ion batteries
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
PL1965798T3 (en) 2005-12-07 2012-02-29 Basilea Pharmaceutica Ag Useful monobactam antibiotics
SI2719388T1 (en) 2006-02-16 2019-06-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
AU2007300531A1 (en) 2006-09-27 2008-04-03 Merck Sharp & Dohme Corp. Novel inhibitors of beta-lactamase
NZ579375A (en) 2007-03-23 2012-02-24 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
CN101861324A (en) * 2007-11-13 2010-10-13 诺瓦提斯国际药物有限公司 Beta-lactamase inhibitors
CA2712783C (en) 2008-01-18 2013-03-19 Timothy A. Blizzard Beta-lactamase inhibitors
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2009140309A2 (en) 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US20110124634A1 (en) 2008-05-13 2011-05-26 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
AU2009335744A1 (en) * 2008-12-17 2010-07-15 Anacor Pharmaceuticals, Inc. Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy) -3H-benzo[c][1,2] oxaborol-1-ol
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
WO2010097675A1 (en) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. An improved preparation process for cefpodoxime proxetil
AR076667A1 (en) 2009-05-12 2011-06-29 Novartis Int Pharm Ltd BETA-LACTAMASA INHIBITORS
US20120238576A1 (en) 2009-06-08 2012-09-20 California Capital Equity, Llc Triazine Derivatives and their Therapeutical Applications
AU2010281439A1 (en) 2009-07-28 2012-03-15 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
US20120329770A1 (en) 2010-02-26 2012-12-27 Gary Igor Dmitrienko Cephalosporin derivatives useful as beta-lactamase inhibitors and compositions and methods of use thereof
NZ602622A (en) 2010-03-31 2015-01-30 Millennium Pharm Inc Derivatives of 1-amino-2-cyclopropylethylboronic acid
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
US8822516B2 (en) 2010-06-10 2014-09-02 Technion Research & Development Foundation Limited Process for the preparation of iodides
ES2691468T3 (en) 2010-08-10 2018-11-27 Rempex Pharmaceuticals, Inc. Derivatives of cyclic boronic acid ester and therapeutic uses thereof
ES2794006T3 (en) 2010-10-26 2020-11-17 Mars Inc Arginase Inhibitors as Therapeutic Agents
AU2011329486A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
WO2013056163A1 (en) 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
SG10201605152SA (en) 2011-12-22 2016-08-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
EP2802593A1 (en) 2012-01-09 2014-11-19 The University of Tromsoe Therapeutic boron-containing compounds
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
RU2654692C2 (en) 2012-12-07 2018-05-22 Венаторкс Фармасьютикалс, Инк. Beta-lactamase inhibitors
JP6324409B2 (en) 2013-01-04 2018-05-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド Boronic acid derivatives and their therapeutic use
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2016509594A (en) 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド Boronic acid derivatives and their therapeutic use
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US8999885B2 (en) 2013-01-09 2015-04-07 General Electric Company Methods of activating charcoal resulting from biomass gasification
WO2014110442A1 (en) 2013-01-10 2014-07-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX361717B (en) 2013-03-15 2018-12-14 Intrexon Corp Boron-containing diacylhydrazines.
DK3140310T3 (en) 2014-05-05 2019-10-21 Rempex Pharmaceuticals Inc SYNTHESIS OF BORONATE SALTS AND USE THEREOF
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3145936B1 (en) 2014-05-19 2020-09-30 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) * 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
RU2686740C2 (en) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Beta-lactamase inhibitors
EP3164406A4 (en) 2014-07-01 2018-04-04 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016065282A1 (en) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016172208A1 (en) 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
ES2894251T3 (en) 2016-06-30 2022-02-14 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof

Also Published As

Publication number Publication date
US10004758B2 (en) 2018-06-26
CY2020020I2 (en) 2020-11-25
JP6854861B2 (en) 2021-04-07
SG187757A1 (en) 2013-03-28
AU2011289615B2 (en) 2015-05-07
CN103180328B (en) 2016-10-26
ES2691468T3 (en) 2018-11-27
KR101987091B1 (en) 2019-06-10
KR102205755B1 (en) 2021-01-22
NO2019013I1 (en) 2019-03-28
LTPA2020519I1 (en) 2020-08-10
EP3666778A1 (en) 2020-06-17
NZ607354A (en) 2015-01-30
WO2012021455A1 (en) 2012-02-16
LT3412676T (en) 2020-07-27
KR102087313B1 (en) 2020-03-11
EP2603514B1 (en) 2018-07-18
EP3412676A1 (en) 2018-12-12
RU2599791C2 (en) 2016-10-20
EP2603514A1 (en) 2013-06-19
IL224564A (en) 2017-02-28
PL3412676T3 (en) 2021-04-06
CN103180328A (en) 2013-06-26
CY2020019I1 (en) 2020-11-25
US11090319B2 (en) 2021-08-17
JP2021073212A (en) 2021-05-13
PT3412676T (en) 2020-05-19
US20120040932A1 (en) 2012-02-16
HUS1900018I1 (en) 2019-05-28
US20160220591A1 (en) 2016-08-04
BR112013003045B1 (en) 2021-08-31
MX348653B (en) 2017-06-21
EP3666778B1 (en) 2021-11-10
JP2013535502A (en) 2013-09-12
KR20130099923A (en) 2013-09-06
CO6680667A2 (en) 2013-05-31
EP2603514A4 (en) 2014-10-29
JP6602742B2 (en) 2019-11-06
HUE040086T2 (en) 2019-02-28
CY2020020I1 (en) 2020-11-25
MX2013001517A (en) 2013-04-29
RS60310B1 (en) 2020-07-31
HUE048859T2 (en) 2020-08-28
HUS1900017I1 (en) 2019-05-28
US20180207183A1 (en) 2018-07-26
MY188960A (en) 2022-01-14
US9296763B2 (en) 2016-03-29
JP6266978B2 (en) 2018-01-24
LTPA2020521I1 (en) 2020-08-10
US11684629B2 (en) 2023-06-27
US10172874B2 (en) 2019-01-08
AU2011289615A1 (en) 2013-03-21
US20200222434A1 (en) 2020-07-16
US20180214465A1 (en) 2018-08-02
KR20190066084A (en) 2019-06-12
KR20200028043A (en) 2020-03-13
LTC3412676I2 (en) 2022-09-12
CY2020019I2 (en) 2020-11-25
CL2013000399A1 (en) 2013-08-23
US20230277571A1 (en) 2023-09-07
PL2603514T3 (en) 2019-04-30
US8680136B2 (en) 2014-03-25
US20180071325A1 (en) 2018-03-15
JP2020002178A (en) 2020-01-09
JP2017052794A (en) 2017-03-16
EP3412676B1 (en) 2020-02-12
HRP20200741T1 (en) 2020-10-16
JP7227282B2 (en) 2023-02-21
CA2807546A1 (en) 2012-02-16
DK2603514T3 (en) 2018-10-29
US9694025B2 (en) 2017-07-04
US10183034B2 (en) 2019-01-22
ES2789177T3 (en) 2020-10-26
US20190076449A1 (en) 2019-03-14
US20220125813A1 (en) 2022-04-28
US10639318B2 (en) 2020-05-05
RU2013104951A (en) 2014-09-20
PT2603514T (en) 2018-11-09
US20130345172A1 (en) 2013-12-26
NO2019014I1 (en) 2019-03-28
CY1123208T1 (en) 2020-11-25
DK3412676T3 (en) 2020-05-04
BR112013003045A2 (en) 2016-06-14
CA2807546C (en) 2022-08-23

Similar Documents

Publication Publication Date Title
LTPA2020519I1 (en) Cyclic boronic acid derivatives, their production method and therapeutic use
EP2941247A4 (en) Boronic acid derivatives and therapeutic uses thereof
EP2941246A4 (en) Boronic acid derivatives and therapeutic uses thereof
EP2587156A4 (en) Glowplug, production method thereof and heating device
DK2934197T3 (en) SMOKE-FREE ORAL TOBACCO PRODUCTS AND MANUFACTURE THEREOF
SMT201500233B (en) METHODS TO DETECT MEDICINE ANTI-CORPS
DK2894151T3 (en) IMIDAZOLINE DERIVATIVES, MANUFACTURING METHODS AND USE IN MEDICINE
DK2384731T3 (en) Medical trolley
BR112012029028A2 (en) laryngoscope, laryngoscope arms and manufacturing methods
BR112012032494A2 (en) product, use and method of production of a product
DK2819974T3 (en) FERTILIZER, USE AND MANUFACTURING METHOD
DK2809318T3 (en) Ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
HUP1000366A2 (en) Novel proteins, their production process and use tereof
EP2805956A4 (en) Gambogenic acid derivatives, preparation method and application thereof
EP2881137A4 (en) Medical instrument, and medical-instrument production method
EP2886548A4 (en) Method for producing borinic acid derivative, and novel borinic acid derivative
PL2912039T3 (en) Derivatives of camptothecin, a method of producing them and their use
BR112012018072A2 (en) anhydrous formulation, method and use of the formulation
LTPA2021004I1 (en) 4-Imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
FR2966066B1 (en) LOST MODEL MOLDING PROCESS
IT1403367B1 (en) WIRELESS ELECTROMEDICAL DEVICE
SI3412676T1 (en) Cyclic boronic acid ester derivatives, method for the preparation and therapeutic uses thereof
PL398891A1 (en) Production method of 4 ', 5,6,7-tetrahydroxyflavanone and 4', 5,7,8-tetrahydroxyflavanone
AU2012904774A0 (en) Improvements to cyclic cranked system, device and method
BRDI7101145S (en) SETTING APPLIED TO JEWELRY.